Prescription Drug Affordability Board Exempt Orphan Drugs
Impact
The bill directly affects the regulation of pharmaceutical prices in Colorado, particularly for orphan drugs, which are often more expensive to produce and essential for treating rare conditions. By removing these drugs from affordability reviews, the bill seeks to encourage the development and availability of such specialty medications without the pressures of price caps that might restrict access or development incentives.
Summary
Senate Bill 060 (SB060) proposes an amendment to the authority of the Colorado Prescription Drug Affordability Review Board concerning certain drugs. Specifically, this bill exempts drugs classified by the federal Food and Drug Administration (FDA) as being for a rare disease or condition from the board's affordability review process. This means that the board cannot assess these drugs for cost containment or impose upper payment limits, thereby protecting them from potential price regulation under state affordability laws.
Contention
Notably, the discussions surrounding SB060 likely included a range of opinions regarding the balance between affordability and accessibility of necessary medications. Supporters may argue that exempting these drugs could prevent discouragement of pharmaceutical companies from investing in research for rare diseases, while opponents might raise concerns over potential unchecked pricing and affordability issues for patients in need of these critical medications. Legislative debates would have likely focused on the broader implications for healthcare costs and the efficacy of the board's regulatory role in ensuring affordability for all prescription drugs.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.